Fragment 176-191, Mod GRF 1-29 & Ipamorelin | The Ultimate Metabolic Stack

• Mod GRF 1-29 (GHRH Analog): Acts on pituitary GHRH receptors to stimulate the production of endogenous growth hormone. Research suggests its influence extends to studying intestinal inflammation and cardiac function.
• Ipamorelin (GHSR Agonist): A highly selective secretagogue that triggers GH release via the ghrelin receptor pathway. While it is studied for bone growth and cellular repair, its potential to increase appetite is a key variable in this blend.
• Fragment 176-191 (Lipolytic Fragment): Consisting of the final 16 amino acids of the hGH molecule, this segment specifically targets fat-reduction pathways. It is included to study the mitigation of fat accumulation that may occur during growth hormone stimulation.

• Maximized GH Output: Studies suggest that combining a GHRH analog with a GHSR agonist may achieve the absolute maximal endogenous GH release from the anterior pituitary somatotrophs.
• Selective Body Composition: This blend allows researchers to investigate “lean growth” models. By adding the lipolytic Fragment 176-191, the potential fat-increasing effects of ghrelin receptor activation may be theoretically neutralized.
• Molecular Stability: This formulation utilizes the tyrosine-substituted version of the HGH fragment (sometimes called AOD-9604) to ensure superior resistance to enzymatic degradation during experimental trials.
• Targeted Pathway Study: Provides a framework to explore non-redundant signaling, where the anabolic benefits of GH are studied in parallel with direct lipid catabolism.